Ingenium Therapeutics develops natural killer (NK) cell therapies to target and destroy intractable leukemia cells by enhancing the immune response within the tumor microenvironment. The company focuses on creating memory-like NK cells and engineered biologics to improve cancer recognition and treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often fail to eradicate leukemia cells completely, leading to relapse and disease progression. The tumor microenvironment (TME) can suppress the activity of immune cells, hindering their ability to effectively target and destroy cancer cells. Existing natural killer (NK) cell therapies have limitations in overcoming the immunosuppressive effects of the TME and achieving durable responses.
Solution
Ingenium Therapeutics is developing a novel approach to cancer immunotherapy, focusing on enhancing the innate immune system's ability to eliminate intractable leukemia. The company's platform centers around memory-like NK cells, a subset of NK cells with superior anti-tumor activity and persistence. Ingenium is also developing engineered biologics, such as engagers, designed to improve NK cell recognition of cancer cells and enhance their function within the challenging tumor microenvironment. By combining optimized NK cells with biologics that counteract TME-mediated suppression, Ingenium aims to create more effective and durable cancer therapies. These next-generation therapies are designed to overcome the limitations of current approaches and improve patient outcomes.
Target Audience
The primary target audience includes patients with leukemia and other hematological malignancies, as well as clinicians and researchers in the fields of oncology and immunotherapy.
Features
- Memory-like NK cell platform with enhanced cytotoxicity and longevity compared to conventional NK cells
- Engineered biologics (e.g., engagers) to improve NK cell targeting and activation within the tumor microenvironment
- Development of CAR-NK cells with genetic modifications for enhanced cancer cell recognition
- Protein-based therapeutics, including peptides, to augment NK cell function
- Focus on overcoming the immunosuppressive effects of the tumor microenvironment
- Pipeline of novel anti-cancer biologics targeting various leukemia subtypes